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Abstract
Background:  A high rate of resistance to 3rd  generation cephalosporins among
Enterobacteriaceae isolates from Egypt has been previously reported. This study aims to
characterize the resistance mechanism (s) to extended spectrum cephalosporins among resistant
clinical isolates at a medical institute in Cairo, Egypt.
Methods: Nonconsecutive Klebsiella pneumoniae (Kp), Enterobacter cloacae (ENT) and Escherichia
coli (EC) isolates were obtained from the clinical laboratory at the medical institute. Antibiotic
susceptibility was tested by CLSI disk diffusion and ESBL confirmatory tests. MICs were determined
using broth microdilution. Isoelectric focusing (IEF) was used to determine the pI values, inhibitor
profiles, and cefotaxime (CTX) hydrolysis by the β-lactamases. PCR and sequencing were
performed using blaCTX-M and ISEcp1-specific primers, with DNA obtained from the clinical isolates.
Conjugation experiments were done to determine the mobility of blaCTX-M.
Results: All five clinical isolates were resistant to CTX, and were positive for ESBL screening. IEF
revealed multiple β-lactamases produced by each isolate, including a β-lactamase with a pI of 8.0 in
Kp and ENT and a β-lactamase with a pI of 9.0 in EC. Both β-lactamases were inhibited by clavulanic
acid and hydrolyzed CTX. PCR and sequence analysis identified blaCTX-M-14 in Kp and ENT and a
blaCTX-M-15 in EC. Both blaCTX-M-14 and blaCTX-M-15 were preceded by ISEcp1 elements as revealed by
partial sequence analysis of the upstream region of the blaCTX-M genes. blaCTX-M-15 was transferable
but not blaCTX-M-14.
Conclusion: This is the first report of CTX-M-14 in Kp and ENT isolates from Egypt, the Middle
East and North Africa.
Background
Recent studies on Enterobacteriaceae isolates from Egypt
have reported a resistance rate to third generation cepha-
losporins of 70% [1,2]. A survey, carried out in 2001–
2002 and covered medical centers in Northern and South-
ern European countries, Egypt, Lebanon, Saudi Arabia
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and South Africa, reported the highest incidence of
extended spectrum β-lactamases (ESBLs)-producing iso-
lates in Egypt [3].
CTX-M ESBLs are the most prevalent ESBLs worldwide [4].
Recently, CTX-M ESBLs have been reported in Egypt [5],
with CTX-M-15 being the most common ESBL reported in
the Middle East region and North Africa [6,5,7]. However,
CTX-M-14 has also been detected in Escherichia coli iso-
lates from Egypt and Tunisia [5,8]. But CTX-M-14 has not
been reported in Klebsiella pneumoniae isolates in this geo-
graphical region before.
CTX-Ms are class A ESBLs that are most active against cefo-
taxime [9]. However, some CTX-Ms can hydrolyze ceftazi-
dime such as CTX-M-15 and CTX-M-19 [10,11]. The
nucleotide sequences of blaCTX-M genes are highly related
to the nucleotide sequence of Kluyvera spp. [12,13].
Clinical isolates of K. pneumoniae, Enterobacter cloacae and
E. coli were sent from the clinical microbiology laboratory
in a medical institute in Cairo, Egypt to investigate the
mechanism (s) responsible for resistance to extended
spectrum cephalosporins.
Methods
Bacterial strains
Five clinical isolates were sent on blood agar plates from
the clinical laboratory at the medical institute. The isolates
were three nonconsecutive K. pneumoniae isolates and one
E. coli isolate, which were collected from chest wound
swabs from patients in an adult surgical ICU ward. In
addition, one E. cloacae isolate was obtained from central
venous line of a patient in the pediatric ICU ward.
Informed written consents were obtained from patients.
Identification of the isolates was performed using Phoe-
nix® bacterial identification panels (NMIC/ID-107) and
API® 20E strips (Biomerieux SA, Marcy-l'Etoile, France).
Susceptibility test
Antibiotic susceptibility was tested using disk diffusion
with the following drugs: cefotaxime, ceftazidime, tetracy-
cline, gentamicin, amikacin, ciprofloxacin, and sulfame-
thoxazole. ESBL production was investigated using
cefotaxime and ceftazidime, alone and in combination
with clavulanic acid (BBL, Beckton Dickinson, Sparks,
MD., USA) as recommended by the Clinical Laboratory
Standard Institute [14]. The minimum inhibitory concen-
trations (MICs) of cefpodoxime, cefepime, cefoxitin,
aztreonam, and imipenem, and the β-lactam/β-lactamase
inhibitor combinations: cefpodoxime/clavulanate, and
cefepime/clavulanate were determined by broth microdi-
lution according to CLSI guidelines [14] using TREK
microbroth dilution panels (Cleveland, Ohio, USA).
β-lactamase characterization
Crude β-lactamase extracts from the clinical isolates and
strains producing reference β-lactamases were assessed for
β-lactamase pI values, inhibitor and substrate characteris-
tics by isoelectric focusing (IEF) [15].
β-lactamase gene identification and analysis of upstream 
region
PCR amplification was used to identify the presence of
blaCTX-M-15-like in the E. coli clinical isolate, and blaCTX-M-14-
like in K. pneumoniae and E. cloacae isolates using specific
primers that targeted CTX-M group I and IV; respectively
[16]. The presence of genes encoding TEM and SHV
enzymes was analyzed by PCR [17]. The MgCl2 concentra-
tion used was 2 mM for blaTEM and blaSHV PCR and 1.5 mM
for  blaCTX-M PCR. Template DNA preparation and PCR
amplifications were carried out as previously described
[17].
PCR amplification and sequencing of the full-length
blaCTX-M-14-like  gene was performed, using primers that
flanked the gene (CTXM14 F1 5'-GAG TGT TGC TCT GTG
GAT AAC-3', designed using accession number AF252622
and annealing at positions 1857–1876; and CTX14R4 5'-
GTT ACA GCC CTT CGG CGA TG-3' designed using acces-
sion number AF252622 and annealing at positions 2617-
2598). Sequence analysis of the blaCTX-M-15-like gene was
done using CTX3 FLF 5'-CGT CTC TTC CAG AAT AAG G-
3', designed using accession number AY995205 and
annealing at positions 169–187; and CTX3 FLR 5'-GTT
TCC CCA TTC CGT TTC CGC-3' designed using accession
number AY995205 and annealing at positions 1092-
1072).
Sequence analysis of the 524 bp upstream region of the
structural gene for blaCTX-M-15 was performed on an ampli-
fied product generated using primers ISEcp1 (AGC CAA
ATA CGA CAT GGC GGT G, this primer corresponds to
nucleotide numbers 1179 to 1200 of the sequence with
accession no. DQ658222) and CTX15 (CTT CCT AAC
AAC AGC GTG AC, this primer corresponds to nucleotide
numbers 261-242 of the sequence with the accession
number AY995205). The 184 bases upstream of the
blaCTX-M-14  were sequenced using the CTX14 upstream
primer (GCA CCT GCG TAT TAT CTG C, this primer cor-
responds to nucleotide numbers 184-166 of the sequence
with the accession number DQ359215).
Five microliters aliquots of PCR products were analyzed
by gel electrophoresis with 1% agarose gels (BioRad, Her-
cules, Calif.) in TAE buffer. Gels were stained with ethid-
ium bromide (10 mg/L) and visualized by UV
transilluminator.BMC Infectious Diseases 2009, 9:84 http://www.biomedcentral.com/1471-2334/9/84
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The PCR products were purified with Microcon YM-50
columns (Micon bioseparations, Bedford, MS, USA). The
amplicons were sequenced using automated PCR cycle
sequencing with dye terminator chemistry using ABI
PRISM 3100 Genetic Analyzer and Data collection soft-
ware (version 3.7).
The nucleotide and deduced amino acid sequences were
analyzed and compared using BLAST software available
online at http://www.ncbi.nlm.nih.gov/BLAST.
Conjugation experiments
To determine whether the cefotaxime resistance was car-
ried on a conjugative plasmid, conjugation experiments
were performed with K. pneumoniae (only one isolate was
tested), E. coli and E. cloacae as donors and the E. coli (Na
azideR) as the recipient. The filter mating technique was
carried out as previously described [18]. Transformants
were selected on Mueller Hinton agar plates containing
sodium azide 200 mg/L and cefotaxime 2 mg/L and were
confirmed for blaCTX-M  genes using PCR as described
above.
Results and discussion
Antimicrobial susceptibility
Disk diffusion showed that all isolates were resistant to
cefotaxime and positive for ESBL production by disk con-
firmatory test using cefotaxime/clavulanate and ceftazi-
dime/clavulanate (Table 1). The MICs of β-lactams and β-
lactam/inhibitor combinations were determined by broth
microdilution technique. All clinical isolates were resist-
ant to cefpodoxime, cefepime and resistant or intermedi-
ately resistant to aztreonam. The phenotypic ESBL
microdilution confirmatory test was positive, showing a
decrease by 7 doubling dilutions in the presence of clavu-
lanic acid (Table 2). The K. pneumoniae clinical isolates
were also resistant to other non-β-lactam antibiotics such
as tetracycline, gentamicin and fluoroquinolones (Table
1).
Isolates of the Enterobacteriaceae producing CTX-M
ESBLs are resistant to cefotaxime (MICs ≥ 64 mg/L) [9]
and cefepime (MICs ≥ 32 mg/L) [19-22], but are suscepti-
ble or intermediate to ceftazidime [9]. The phenotypic
characteristics of the clinical isolates in this study sug-
gested the presence of CTX-M ESBLs. Screening using
ceftazidime alone is not sufficient for organisms produc-
ing CTX-M ESBLs [16]. However, CTX-M-15 has been
reported to possess some hydrolytic activity against
ceftazidime [10]. The E. coli isolate producing CTX-M-15
was intermediate to ceftazidime using disk susceptibility
test (Table 1).
Characterization of β-lactamases
Isoelectric focusing (IEF) of crude sonicates of the clinical
isolates was done by a cefotaxime/β-lactamase inhibitor
overlay technique. Two enzymes focused at pI values of
8.0 and 9.0, were inhibited by clavulanic acid, and
showed an extended spectrum of activity by hydrolyzing
cefotaxime (Table 2). PCR and sequence analysis identi-
fied blaCTX-M-14 in one isolate of K. pneumoniae (KP 4) and
the E. cloacae isolate, and blaCTX-M-15 in the E. coli clinical
isolate (Table 2). Only one K. pneumoniae isolate was eval-
uated by sequence analysis because all three of the K.
pneumoniae isolates showed the same enzymes on the IEF
gel (Table 2).
All isolates produced multiple β-lactamases that were
inhibited by clavulanate: K. pneumoniae (pI values 5.4,
6.3, 7.6, and 8.0), E. cloacae (pI values 6.3, 7.6, 8.0), and
E. coli (pI values, 5.4, 6.0, 6.6 and 9.0) (Table 2). The
blaTEM gene was detected in all K. pneumoniae and E. coli
Table 1: Susceptibility data of the clinical isolates and the transconjugant
Zone diameter of inhibition (mm)
Clinical Isolate CTX CTX/CLA CAZ CAZ/CLA TET GEN AMK CIP SXT
Kp4 6 18 18 25 6 8 20 6 ND
Kp8 6 16 19 26 6 8 20 6 ND
K p 1 5 6 1 61 82 56 8 2 0 6 N D
E N T 1 02 02 12 5 2 0 1 7 2 1 3 0 N D
E C 9 2 21 52 6 1 9 1 9 2 0 3 2 6
TcECa 11 31 20 32 25 ND ND ND 33
EC Na azR 34 32 29 29 22 23 ND 28 30
Isolates were tested for susceptibility using disk diffusion according to CLSI guidelines [14].
CTX: cefotaxime, CTX/CLA: cefotaxime/clavulanic acid, CAZ: ceftazidime, CAZ/CLA: ceftazidime/clavulanic acid, TET: tetracycline, GEN: 
gentamicin; AMK: amikacin; CIP: ciprofloxacin, SXT: sulfamethoxazole/trimethoprim,
TcEC: transconjugant carrying plasmid encoding blaCTX-M-15.
EC Na azR: recipient strain resistant to sodium azide
a Transconjugant was tested by PCR experiment for blaCTX-M-15-like using specific primers [16].
ND: Not determinedBMC Infectious Diseases 2009, 9:84 http://www.biomedcentral.com/1471-2334/9/84
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isolates, and corresponded to the β-lactamase band that
focused at pI value of 5.4 when evaluated by IEF (Table 2).
The blaSHV gene was present in the K. pneumoniae isolates
(β-lactamase band focusing at pI value, 7.6-Table 2). The
β-lactamase band that focused at pI value of 7.6 in the E.
cloacae isolate was most likely not an SHV-enzyme since
SHV-specific PCR was negative. Further sequencing exper-
iments for the blaTEM and blaSHV genes were not done.
Analysis of the upstream sequence of blaCTX-M-14 and of
blaCTX-M-15  revealed the presence of the right terminal
inverted repeat of the insertion sequence ISEcp1 and the
putative promoter region (-10 and -35) associated with
this element [23].
The results of the conjugation experiment showed that
blaCTX-M-15 was carried on a conjugative plasmid (Table 1).
The movement of blaCTX-M-15 was verified in the transcon-
jugant using CTX-M-group 1-specific PCR [16]. The blaCTX-
M-14 gene was not mobilized by conjugation.
A surveillance report on antibiotic resistance in the South-
eastern Mediterranean region screened only E. coli isolates
from different medical centers in Egypt [2]. Other impor-
tant nosocomial isolates such as K. pneumoniae and E.
cloacae were not evaluated in that study [2]. A recent out-
break was reported in a neonatal intensive care unit in
Cairo, Egypt, in which 80% of the isolates were K. pneumo-
niae, of which 58% were ESBL producers [24]. Therefore,
it is important not to limit extended-spectrum cepha-
losporin susceptibility screening in Egypt to E. coli but to
include K. pneumoniae as well as other Enterobacteriaceae
such as E. cloacae.
It is important for clinical microbiologists in Egyptian
hospitals to screen for CTX-M ESBL producers. In addi-
tion, clinical microbiologists and physicians need to be
aware that these enzymes are present in many different
types of Enterobacteriaceae. This information is essential
for determining the most appropriate empirical antibiotic
therapy.
Conclusion
This study is the first documentation of CTX-M-14 ESBLs
in K. pneumoniae and E. cloacae isolates in Egypt as well as
the Middle East region and North Africa.
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Clinical Isolate Enzyme characteristicsa Gene (s) detected by PCRb MIC (mg/L) of:
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Clox CLA
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that flanked the full-length genes (See Methods section).
c PCR was not done to detect the gene that corresponds to the β-lactamase band on IEF gel.
d β-lactamase band focusing at pI value of 8.9, which is inhibited by cloxacillin, corresponds to the chromosomal ampC gene of E. cloacae (PCR data 
not shown).
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